<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03607656</url>
  </required_header>
  <id_info>
    <org_study_id>LONGHUA-2018-SH</org_study_id>
    <nct_id>NCT03607656</nct_id>
  </id_info>
  <brief_title>The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer</brief_title>
  <acronym>CHANGE</acronym>
  <official_title>The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Province Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label study done in 3 hospitals in China. Patients with stage IIIB
      and IIIC gastric cancer who undergo curative D2 gastrostomy will be randomly assigned after
      surgery to receive adjuvant chemotherapy with oxaliplatin and capecitabine, or adjuvant
      chemotherapy combined Traditional Chinese treatment. The primary outcome was disease-free
      survival and 3-year disease-free survival rate in the intention-to-treat population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the Traditional Chinese Medicine combined adjuvant
      chemotherapy in the treatment of stage IIIb and IIIc gastric cancer through randomized
      controlled trial.

      Metastasis and recurrence is the primary cause in decreasing the survival time of gastric
      cancer patients who experienced radical operation. Among whom, patients with stage IIIB and
      IIIC are especially in high risk of metastasis and recurrence, result in a significant poor
      survival time than patients with earlier stages.

      Oxaliplatin with capecitabine is the standard adjuvant chemotherapy for curative D2
      gastrostomy gastric cancer, contribute the 3-year disease free survival rate of 74% in ITT,
      and 61% in stage IIIB sub-group. Meanwhile, Traditional Chinese Medicine (TCM) treatment has
      been used for thousands of years in Chinese clinical practices. In China, the clinical
      curative effect of TCM in the treatment of gastric cancer has been part of affirmation. Some
      reports with large samples of clinical research show that the TCM is effective and safety for
      gastric cancer.In order to evaluate efficacy on TCM combined adjuvant chemotherapy in IIIB
      and IIIC gastric cancer, we design this randomized, open-label study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year Disease Free Survival rate</measure>
    <time_frame>36 months</time_frame>
    <description>The rate refers to cases that see first tumor metastasis or recurrence or death of any cause from randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety （adverse effects）</measure>
    <time_frame>36 months</time_frame>
    <description>Using NCI-CTC standard to record adverse effects of chemotherapy and treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-C30 scale</measure>
    <time_frame>36 months</time_frame>
    <description>Using the EORTC QLQ-C30 scale (European Organization for Research on Treatment of Cancer Quality of Life Questionnaire-Core 30) to evaluate the quality of life of patients. The scale includes 14 aspects: physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning, fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial problem, with each aspect scores from one point to four points (lower points represent a better quality of life), and a general quality of life scores from one point to seven points (higher points represent a better quality of life).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Gastric Cancer Stage IIIB</condition>
  <condition>Gastric Cancer Stage IIIC</condition>
  <arm_group>
    <arm_group_label>TCM combines CapOX/SOX/S-1+D/FLOT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Traditional Chinese Medicine oral taken twice a day for at least 3 months combined with chemotherapy.
The chemotherapy can choose intravenous oxaliplatin 130 mg/m(2) on day 1 plus oral capecitabine 1000 mg/m(2) twice daily on days 1-14, every 21 days; or intravenous oxaliplatin 100 mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 40mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 50mg/m(2) on day 1 plus intravenous oxaliplatin 85 mg/m(2) on day 1 plus 5-FU intravenously CIV24h on day 1, every 14 days; Each participant shoud take eight (8) cycles of chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CapOX/SOX/S-1+D/FLOT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The chemotherapy can choose intravenous oxaliplatin 130 mg/m(2) on day 1 plus oral capecitabine 1000 mg/m(2) twice daily on days 1-14, every 21 days; or intravenous oxaliplatin 100 mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 40mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 50mg/m(2) on day 1 plus intravenous oxaliplatin 85 mg/m(2) on day 1 plus 5-FU intravenously CIV24h on day 1, every 14 days; Each participant shoud take eight (8) cycles of chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin powder injection</description>
    <arm_group_label>CapOX/SOX/S-1+D/FLOT</arm_group_label>
    <arm_group_label>TCM combines CapOX/SOX/S-1+D/FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine tablet</description>
    <arm_group_label>CapOX/SOX/S-1+D/FLOT</arm_group_label>
    <arm_group_label>TCM combines CapOX/SOX/S-1+D/FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TCM</intervention_name>
    <description>TCM decoction orally taken twice a day for at least 3 months</description>
    <arm_group_label>TCM combines CapOX/SOX/S-1+D/FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>S-1 capsule</description>
    <arm_group_label>CapOX/SOX/S-1+D/FLOT</arm_group_label>
    <arm_group_label>TCM combines CapOX/SOX/S-1+D/FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel injection</description>
    <arm_group_label>CapOX/SOX/S-1+D/FLOT</arm_group_label>
    <arm_group_label>TCM combines CapOX/SOX/S-1+D/FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>5-FU injection</description>
    <arm_group_label>CapOX/SOX/S-1+D/FLOT</arm_group_label>
    <arm_group_label>TCM combines CapOX/SOX/S-1+D/FLOT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven gastric carcinoma with radical operation, TNM (primary tumor,
             regional nodes, metastasis) stage IIIb or IIIc （The Eighth Edition American Joint
             Committee on Cancer [AJCC] gastric cancer staging）;

          -  Karnofsky performance status higher than 70;

          -  Adequate hepatic, renal, cardio and hematologic function;

          -  With patients' consent and comply to long term follow-up.

        Exclusion Criteria:

          -  Gastrectomy beyond D2, or TNM stage beyond Ⅲb and Ⅲc;

          -  Histological type beyond gastric carcinoma;

          -  Conversion chemotherapy before surgery;

          -  Concurrent cancer;

          -  Women of gravid or lactating; patients with mental illness;

          -  Uncontrolled significant comorbid conditions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aiguang Zhao, M.D.,Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Longhua Hospital Shanghai University of Traditional Chinese Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aiguang Zhao, M.D.,Ph.D</last_name>
    <phone>13661472241</phone>
    <email>2538312201@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nida Cao, M.D.</last_name>
    <phone>13818949357</phone>
    <email>amandatsao77@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Longhua Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aiguang Zhao, M.D.,Ph D.</last_name>
      <phone>13661472241</phone>
      <email>2538312201@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Nida Cao, M.D.</last_name>
      <phone>13818949357</phone>
      <email>amandatsao77@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012 Jan 28;379(9813):315-21. doi: 10.1016/S0140-6736(11)61873-4. Epub 2012 Jan 7.</citation>
    <PMID>22226517</PMID>
  </reference>
  <reference>
    <citation>Xu Y, Zhao AG, Li ZY, Zhao G, Cai Y, Zhu XH, Cao ND, Yang JK, Zheng J, Gu Y, Han YY, Zhu YJ, Yang JZ, Gao F, Wang Q. Survival benefit of traditional Chinese herbal medicine (a herbal formula for invigorating spleen) for patients with advanced gastric cancer. Integr Cancer Ther. 2013 Sep;12(5):414-22. doi: 10.1177/1534735412450512. Epub 2012 Jul 9.</citation>
    <PMID>22781545</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 1, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai University of Traditional Chinese Medicine</investigator_affiliation>
    <investigator_full_name>zhaoaiguang</investigator_full_name>
    <investigator_title>Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

